Article

Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors

Yu-zhe Wang1,2, De-hua Yang1,2,3, Ming-wei Wang1,2,3,4
1 The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2 University of Chinese Academy of Sciences, Beijing 100049, China
3 The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
4 Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
Correspondence to: De-hua Yang: dhyang@simm.ac.cn, Ming-wei Wang: mwwang@simm.ac.cn,
DOI: 10.1038/s41401-021-00758-6
Received: 2 April 2021
Accepted: 4 August 2021
Advance online: 26 August 2021

Abstract

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are regarded as ‘incretins’ working closely to regulate glucose homeostasis. Unimolecular dual and triple agonists of GLP-1R and GIPR have shown remarkable clinical benefits in treating type 2 diabetes. However, their pharmacological characterization is usually carried out in a single receptor-expressing system. In the present study we constructed a co-expression system of both GLP-1R and GIPR to study the signaling profiles elicited by mono, dual and triple agonists. We show that when the two receptors were co-expressed in HEK 293T cells with comparable receptor ratio to pancreatic cancer cells, GIP predominately induced cAMP accumulation while GLP-1 was biased towards β-arrestin 2 recruitment. The presence of GIPR negatively impacted GLP-1R-mediated cAMP and β-arrestin 2 responses. While sharing some common modulating features, dual agonists (peptide 19 and LY3298176) and a triple agonist displayed differentiated signaling profiles as well as negative impact on the heteromerization that may help interpret their superior clinical efficacies.
Keywords: glucagon-like peptide-1 receptor; glucose-dependent insulinotropic peptide receptor; peptide 19; LY3298176; heteromerization; type 2 diabetes

Article Options

Download Citation

Cited times in Scopus